Source: CureToday articles
The phase 1/2 STARLIGHT-1 trial has dosed the first patient in the second cohort of the study evaluating EB103 in advanced B-cell non-Hodgkin’s lymphomas.
Recent Content
- CDC Clarifies That Kids May Receive COVID-19 Vaccine Through Shared Clinical Decision-Making
- Day 4: Top Takeaways from ASCO25
- Understanding the Side Effects of RLY-2608 in HR+, HER2– Breast Cancer
- FDA Approves mRNA-1283 COVID-19 Vaccine for Adults 65 and Older, Those With Underlying Conditions
- Q&A: High-fiber, plant-based diet may lower multiple myeloma risk
- Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in cUTIs Ends Early After Meeting Primary End Point
- New Jersey Society of Health-System Pharmacy Hosts 2nd Annual Pharmacy Leader and Pharmacy Technician Symposium
- Imlunestrant Alone or With Verzenios Improved PROs in Advanced Breast Cancer
- Informing Treatment Decisions Using a 14-Gene Assay in Early Non-Small Cell Lung Cancer
- ASCO 2025: Oncology Pathway Tools Show Consistent Usage Across Patient Groups